Bao-Cai Xing

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions—A comparison of conventional ultrasound and contrast-enhanced CT

Zhihui Fan, Ying Li, Kun Yan et al. · European Journal of Radiology · 2013 · 66 citations

Medical Ultrasound, Medical Imaging, Contrast-enhanced Ultrasound +8

Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma

Xiaodong Wang, Jungang Hu, Guang Cao et al. · Radiology · 2016 · 57 citations

Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis

Lijun Wang, Zhongyi Zhang, Xiaoluan Yan et al. · World Journal of Surgical Oncology · 2018 · 53 citations · Full text